Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-10 5:25 pm Sale |
2025-03-31 | 13G | Chemomab Therapeutics Ltd. CMMB |
Sphera Funds Management Ltd. | 900,428 4.780% |
-314,147 (-25.86%) |
Filing History |
| 2024-11-29 3:04 pm Purchase |
2024-11-14 | 13D | Chemomab Therapeutics Ltd. CMMB |
Mor George Adi | 898,221 4.800% |
150,776 (+20.17%) |
Filing History |
| 2024-11-21 10:59 am Purchase |
2024-11-21 | 13G | Chemomab Therapeutics Ltd. CMMB |
Otto Erik | 1,155,000 6.100% |
1,155,000 (New Position) |
Filing History |
| 2024-09-16 4:34 pm Sale |
2024-09-12 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 1,860,906 9.990% |
-409,185 (-18.03%) |
Filing History |
| 2024-08-20 2:36 pm Purchase |
2024-07-25 | 13G | Chemomab Therapeutics Ltd. CMMB |
Sphera Funds Management Ltd. | 1,214,575 6.560% |
1,214,575 (New Position) |
Filing History |
| 2024-03-11 7:19 pm Unchanged |
2024-03-11 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 16.000% |
0 (Unchanged) |
Filing History |
| 2023-11-15 4:35 pm Unchanged |
2023-11-14 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 18.300% |
0 (Unchanged) |
Filing History |
| 2023-01-05 4:31 pm Sale |
2023-01-03 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 19.700% |
-49,869,729 (-95.65%) |
Filing History |
| 2022-11-17 4:40 pm Sale |
2022-11-16 | 13D | Chemomab Therapeutics Ltd. CMMB |
Mor George Adi | 747,445 6.400% |
-582,023 (-43.78%) |
Filing History |
| 2022-02-10 4:02 pm Sale |
2021-12-31 | 13G | ANCHIANO THERAPEUTICS LTD ANCN |
Gabriel Capital Management Ltd. | 3,087,040 1.400% |
-5,781,506 (-65.19%) |
Filing History |
| 2022-01-20 06:01 am Purchase |
2021-03-16 | 13D | Chemomab Therapeutics Ltd. CMMB |
Mor George Adi | 1,329,468 11.500% |
1,329,468 (New Position) |
Filing History |
| 2021-04-15 5:28 pm Purchase |
2021-03-16 | 13D | Chemomab Therapeutics Ltd. CMMB |
Access Industries Holdings LLC | 5,057,766 2.360% |
5,057,766 (New Position) |
Filing History |
| 2021-03-26 4:06 pm Purchase |
2021-03-16 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 52,139,820 24.300% |
52,139,820 (New Position) |
Filing History |
| 2021-03-26 08:10 am Purchase |
2021-03-16 | 13G | Chemomab Therapeutics Ltd. CMMB |
THIEL PETER | 22,631,260 10.600% |
22,631,260 (New Position) |
Filing History |
| 2020-12-21 4:31 pm Unchanged |
2020-12-14 | 13D | ANCHIANO THERAPEUTICS LTD ANCN |
Access Industries Holdings LLC | 15,829,397 42.700% |
0 (Unchanged) |
Filing History |
| 2020-12-17 5:36 pm Sale |
2020-12-17 | 13D | ANCHIANO THERAPEUTICS LTD ANCN |
Palisade Medical Equity I LP | 0 0.000% |
-1,848,200 (Position Closed) |
Filing History |
| 2020-05-22 1:34 pm Purchase |
2019-05-21 | 13D | ANCHIANO THERAPEUTICS LTD ANCN |
Palisade Medical Equity I LP | 1,848,200 4.980% |
1,848,200 (New Position) |
Filing History |